News and events
When results are so encouraging, the path is traced: one step at a time towards the cure ~ Hemera’s Team
The importance of scientific communication: Cristiana Vignoli interviewed by Touchpoint on the REMaST® challenge
Touchpoint, an editorial publication focused on the intersection between markets and innovation, dedicated a feature in its February–March print...
REMaST® and the publication in Immunity: growing media attention on the therapeutic platform and its clinical development potential
In January 2026, following the dissemination of the scientific preprint on the cell therapy REMaST published in the international scientific journal...
Osservatorio Terapie Avanzate features Hemera and the regenerative medicine challenge behind REMaST®
Hemera is featured in an article published by Osservatorio Terapie Avanzate, a leading Italian editorial platform focused on scientific information...
Hemera Selected to Pitch at European Deeptech Week in Paris at Women in Biotech Panel
Hemera was selected to present its scientific and entrepreneurial journey at the European Deeptech Week in Paris, one of Europe’s leading events...
National Television TG4 Medicina Features Hemera’s Research: Interview with Ilaria Decimo
The research developed by Hemera was featured in the TG4 Medicina, an in-depth health and innovation program within the national news broadcast of...
Hemera’s research featured on Radio 24: regenerative medicine and new perspectives for spinal cord injuries
The research of Hemera was featured on the Smart City podcast on Radio 24, dedicated to scientific and technological innovation, in an interview...
Interview with CEO Cristiana Vignoli on Rassegna Business: strategic insights on regenerative medicine in spinal cord injuries
Regenerative medicine is currently one of the main areas of research in neurological diseases, driven by increasing interest in the immunological...
Reprogrammed Macrophage Research REMaST® presented at International Symposium in Houston
At the 2026 International Cancer Neuroscience Symposium in Houston (USA) the prestigious scientific forum organized by MD Anderson Cancer Center and...
Hemera featured on the cover of Immunity: full version of the REMaST® study published
Immunity by Cell Press dedicates the cover of Volume 59, Issue 2,10 February 2026 to our study reporting the preclinical data underpinning the...
TG3 Leonardo features an in-depth report on REMaST® and macrophage-based research for nervous system regeneration
The cell therapy REMaST, developed by Hemera for the regeneration of nervous tissue in spinal cord injuries, was the focus of a dedicated report on...
Hemera announces the publication in Immunity of preclinical discoveries on REMaST® for neural tissue regeneration
A peer-reviewed study demonstrates the therapeutic potential of REMaST® in spinal cord repair and neuronal regeneration Hemera is pleased to...
Published in STAR Protocols: Severe contusive preclinical model confirms the preclinical value of REMaST®
Researchers at Hemera, including co-founders Ilaria Decimo and Francesco Bifari and senior scientist Sissi Dolci, have published a key study in STAR...
Cristiana Vignoli and Hemera’s Entrepreneurial Vision Featured in Il Sole 24 Ore
Il Sole 24 Ore insert dedicated to the BFactor Award by the Fondazione Marisa Bellisario was released, featuring a profile of the winners. Among...
Michela Pantaleoni joins Hemera’s Board of Directors
Hemera is pleased to announce the appointment of Michela Pantaleoni to its Board of Directors. Michela brings over twenty years of experience in the...
Hemera on TV: Cristiana Vignoli’s interview on TG2 on RAI 2
CEO Hemera interviews on national italian TV TG2
Cristiana Vignoli Appointed Sole Director of Proemera
Cristiana Vignoli, CEO of Hemera, has been appointed Sole Director of Proemera, the main investment vehicle supporting Hemera since its foundation....
Our CEO Cristiana Vignoli wins the Bellisario BFactor 2025 Award
Cristiana Vignoli, CEO of Hemera, has been awarded the BFactor 2025 Prize as part of the fifth edition of the initiative promoted by the Marisa...
Hemera presents advances in REMaST research at the Science, Technology and Business Days 2025 in Boston
During the Life Sciences session on the third day of the STB Days 2025, an event organized by the General Consulate of Italy in Boston to highlight...
Hemera receives the Seal of Excellence from the European Commission for the REMaST project
Hemera recently participated in the prestigious European program EIC Accelerator, promoted by the European Commission to support high-impact...
European Patent Granted for REMaST: a Key Step in Enhancing Hemera’s Intellectual Property
The European patent for REMaST, Hemera’s proprietary technology for nervous tissue regeneration, has been published in Issue 24/25 of the European Patent Office (EPO) Bulletin on June 11, 2025…
We warmly welcome Statuto Fiduciaria among Hemera’s supporters
We are pleased to announce the entry of Statuto Fiduciaria as a new shareholder, representing the subscribers of the SAFE
Hemera goes to Brussels for the Final Phase of the EIC Accelerator
Hemera is among the 7 Italian startups out of 71 selected across Europe, that successfully passed the second phase of the EIC Accelerator selection process
Hemera at the Chamber of Deputies to Receive the 2025 America Innovation Award
Hemera has been selected among 300 Italian entrepreneurial ventures as a recipient of the America Innovation Award, promoted by the Italy–USA Foundation and presented at the Chamber of Deputies in Rome
Research by Hemera Scientists on Nature Immunology Review
The study titled “Tumor-associated macrophages enhance tumor innervation and spinal cord repair”, to which our researchers contributed, was recently published by Nature Reviews Immunology
Interview with Hemera on Byoblu: Focus on Cell Therapies for Nerve Regeneration
Byoblu interviews Professors Bifari and Locati, co-founders of Hemera, to explore the scientific foundations of our REMaST cell therapy
Hemera Receives a “GO” in Phase 1 of the EIC Accelerator
We are pleased to announce that our proposal successfully passed the short application stage, receiving the first “GO” in the evaluation process.
Cytotherapy Mentions Hemera as One of the Most Promising Players in Cell Therapy
Hemera was recently featured in Cytotherapy, the official journal of the International Society for Cell & Gene Therapy,
Preprint Published: Hemera’s REMaST Research Marks a Breakthrough in Nerve Regeneration
We are pleased to announce the preprint publication of the scientific article presenting the results of our groundbreaking research on the REMaST therapy
Hemera Among the Top 8 Health Startups
We are proud to announce that Hemera has been included in the list of the 8 emerging startups revolutionizing the healthcare sector, as reported by Milano Finanza.
Hemera Wins the 2024 Italian Master Startup Award in the Life Sciences MED-Tech Category
Hemera has been named co-winner of the 2024 IMSA – Italian Master Startup Award in the Life Sciences MED-Tech category, alongside ALBA Robot.
Stay informed on Hemera’s latest activities with our Newsletter.